Introduction
Chronic myelogenous leukemia (CML) results from malignant transformation of a primitive hematopoietic cell. 1 Malignant cells in CML are characterized by a balanced translocation between chromosomes 9 and 22, 2 fusing a truncated BCR gene to sequences upstream of the second exon of c-ABL. The resulting BCR/ABL gene encodes a protein tyrosine kinase with enzymatic activity that is elevated and dysregulated compared to c-Abl. [3] [4] [5] Bcr-Abl has been shown to play a critical role in the pathogenesis of CML. 6, 7 CML typically follows a tri-phasic course, presenting in an initial chronic phase (CP), and then progressing over time through an accelerated phase (AP) and culminating in a terminal blast crisis (BC).
Imatinib mesylate (imatinib) (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ, USA) is a small molecule tyrosine kinase inhibitor that effectively targets the Bcr-Abl kinase. [8] [9] [10] Imatinib results in cytogenetic responses in the majority of CP CML patients and hematologic and cytogenetic responses in a substantial proportion of patients in AP and BC and has emerged as the front-line treatment for newly diagnosed CML. [11] [12] [13] [14] Ongoing clinical studies indicate that the response to imatinib is sustained, at least in the short-term, in the majority of CP CML patients. However, follow-up is limited and the long-term durability of response is still unclear. Although the level of BCR/ ABL transcripts detected by quantitative reverse transcriptasepolymerase chain reaction (Q-PCR) is considerably reduced, complete molecular remissions appear to be rare. 15, 16 In previous studies, we have shown that residual BCR/ABL þ progenitors can persist in patients achieving CCR on imatinib. 17 Others and we have shown that primitive CML progenitors (LTCIC) may be less sensitive to imatinib than more mature cells (CFC). 10, [18] [19] [20] In addition, we have further shown that suppression of CML primitive progenitor growth by imatinib is largely related to inhibition of proliferation and that only a modest increase in apoptosis is seen. 18 Since elimination of malignant progenitors may be key to durable long-term remission, there is a need for improved understanding of the mechanisms underlying incomplete elimination of CML progenitors and for development of approaches to enhance apoptosis of CML progenitor cells in imatinib treated patients.
Here we have investigated the sensitivity of CML progenitors to diverse proapoptotic stimuli known to activate different apoptotic signaling mechanisms. We also evaluated whether Bcr-Abl kinase inhibition by imatinib resulted in enhanced sensitivity of CML progenitors to proapoptotic stimuli. Finally, we investigated the relationship between cellular proliferation and sensitivity to apoptosis.
Materials and methods

Subjects
Heparinized bone marrow samples were obtained from nine CML patients and four normal individuals after informed consent was obtained using guidelines approved by the Institutional Review Board of the City of Hope National Medical Center. CML patients ranged in age from 19 to 68 years, included seven males and two females and were in either CP (n ¼ 6) or AP (n ¼ 3). Two patients had previously received interferon but had been off therapy for 4-9 months. Patients had not received imatinib therapy at the time the sample was collected, with the exception of one patient who had received imatinib for 1 week.
Selection of CD34
þ progenitors
Bone marrow mononuclear cells (BMMNC) were isolated by Ficoll-Hypaque (Sigma, St Louis, MO, USA) density gradient centrifugation. CD34 þ cells were selected from BMMNC using immunomagnetic column separation (Miltenyi Biotech Inc., Auburn, CA, USA).
Treatment of cells with apoptosis-inducing stimuli
CD34
þ cells were cultured for 48 h in serum-free medium (SFM; StemCell Technologies, Vancouver, BC, Canada) supplemented with growth factors (GFs) at concentrations similar to that found in stroma-conditioned medium in long-term bone marrow cultures 21, 22 (GM-CSF (200 pg/ml), G-CSF (1 ng/ml), SCF (200 pg/ml), LIF (50 pg/ml), MIP-1a (200 pg/ml), and IL6 (1 ng/ml)) at 371C in a humidified atmosphere with 5% CO 2 . Cells were exposed to imatinib and/or other apoptosis-inducing agents (arsenic trioxide (arsenic) (As 2 O 3 ; Trisenox, Cell Therapeutics), cytosine arabinoside (Ara-C) (Cytarabine, Bedford Laboratories, Bedford, OH, USA), etoposide (VP-16) (Etoposphos, Bristol Laboratories, Princeton, NJ, USA), C 2 -ceramide (Sigma), tumor necrosis factor alpha (TNFa) (R&D Systems, Minneapolis, MN, USA), and TNFa-related apoptosis-inducing ligand (TRAIL) (R&D Systems)) at the concentrations indicated. Radiation treated cells were exposed to 200-800 cGy from a cesium source at the midpoint of the 48-h culture. GF deprived cells were cultured for 2-6 days in SFM with no added GFs. Cells were subsequently harvested, washed, and assayed for progenitor numbers and apoptosis.
Apoptosis assay
Cells were labeled with Annexin V-FITC (BD-PharMingen, San Diego, CA, USA) and Via-Probe 7-AAD (BD-PharMingen) as previously described 18 and analyzed by flow cytometry. Apoptotic cells were defined as Annexin V-FITC positive and 7-AAD negative.
Progenitor assays
Colony forming cells (CFC) assays were performed by plating CD34 þ cells in methylcellulose progenitor culture for 14-18 days followed by enumeration of CFU-GM and BFU-E colonies as previously described. 18 Evaluation of apoptosis in proliferating vs nonproliferating cells
CD34
þ selected cells were labeled with 5-(and 6-) carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR, USA) as previously described. 18 In some experiments, samples were sorted by flow cytometry to obtain cells with a narrow range of CFSE fluorescence to enhance resolution. Results obtained without sorting were equivalent to those obtained using sorted cells. CFSE labeled cells were cultured in SFM þ GFs, with or without imatinib, arsenic or Ara-C for 48 h. Cultured cells were labeled with Annexin V-PE and analyzed by flow cytometry. Nonproliferating cells were defined as those within a region of CFSE fluorescence that included 495% of paraformaldehyde-fixed, noncultured cells. Proliferating cells were defined as those with fluorescence intensity less than that of the initiating cell population. A proliferation index was calculated based on analysis of the CFSE fluorescence profile using ModFit software (Verity, Topsham, ME, USA).
Evaluation of BCR/ABL status of proliferating vs nonproliferating cells
CML CFSE
þ CD34 þ cells were sorted by flow cytometry, cultured in SFM þ GFs for 48 h in the presence or absence of 1 mM imatinib, and then sorted into nonproliferating and proliferating populations based on CFSE fluorescence intensity. Triple color fluorescence in situ hybridization (FISH) was used to detect the frequency of BCR/ABL gene containing cells in each population. The test was performed by the City of Hope Cytogenetics Core Laboratory using LSI dual color BCR/ABL and 9q34 probes (Vysis, Downers Grove, IL, USA) following the manufacturer's instructions. Real-time quantitative RT-PCR (Q-PCR) for BCR/ABL and b2 microglobulin (B2M) mRNA levels was performed as previously described. 23 Results are expressed as a BCR/ABL:B2M ratio. 
Results
We evaluated the response of CML CD34 þ progenitor cells to a broad range of stimuli capable of inducing apoptosis through different mechanisms. These included chemotherapeutic agents (Ara-C and VP-16), arsenic, sphingosides (C 2 -ceramide), and the death receptor activators TNFa and TRAIL. CML (n ¼ 6) and normal (n ¼ 4) CD34 þ cells were cultured with increasing concentrations of these agents for 48 h and then assayed for apoptosis and suppression of progenitor growth. In addition, we evaluated the effect of radiation or GF deprivation. Significant differences in apoptosis between CML and normal cells were found for Ara-C (0.1 mM; P ¼ 0.045), and for TNFa (1 mg/ml; P ¼ 0.016).
We also evaluated the growth of CML and normal hematopoietic progenitors treated with these agents in methylcellulose progenitor (CFC) assays (Figure 1b) . Conditions leading to increased apoptosis were all associated with a reduction in CFC. There was significantly greater suppression of CML CFC for cells treated with 0.1 mM Ara-C (P ¼ 0.002), 0.5 mg/ml TRAIL (P ¼ 0.003), and all concentrations of arsenic, VP-16, and TNFa tested. Differences between apoptosis and CFC results may reflect effects on proliferation and/or differentiation in addition to effects on viability. In this regard, treatment with TNFa greatly inhibited colony formation but only minimally induced apoptosis, likely reflecting induction of differentiation.
We examined whether imatinib could enhance sensitivity of CML CD34 þ cells to proapoptotic stimuli. CML (n ¼ 4) and normal (n ¼ 3) CD34 þ cells were exposed to imatinib alone or to apoptosis-inducing stimuli in the presence or absence of imatinib for 48 h and assayed for apoptosis ( Figure 2 ) and CFC growth ( Figure 3 ). Exposure to imatinib by itself resulted in a small but significant increase in apoptosis in CML cells (P ¼ 0.027). A smaller, but statistically significant apoptosis increase was also seen for normal cells (P ¼ 0.047) though significantly less than for CML cells (P ¼ 0.04). Apoptosis was significantly greater for CML compared to normal cells treated with combinations of imatinib and 0.01 mM Ara-C (P ¼ 0.046) or TNFa (0.1 mg/ml: P ¼ 0.017; 1.0 mg/ml: P ¼ 0.038). Significant decreases in CFC were found for CML cells treated with a combination of imatinib and arsenic (10 mM) or TRAIL (0.5 mg/ ml) when compared to either agent or imatinib alone. For most combinations CML CFC were significantly more suppressed than normal CFC.
We next investigated the relationship between apoptosis and the proliferative status of CD34 þ cells. Combined CFSE and Annexin V labeling allowed us to track cell division and determine whether apoptosis induced by imatinib (1 mM), Ara-C (0.01 mM) or arsenic (5 mM) alone or in combination occurred in divided (proliferating) or nondivided (nonproliferating) populations (Figure 4a ). Apoptosis in CML cells was restricted to dividing cells and no increase in apoptosis was seen in the nondividing population (Table 1 and Figure 4b) . Apoptosis of proliferating CML cells following Ara-C exposure was reduced when Ara-C was combined with imatinib (P ¼ 0.009). In the absence of any added agents, CML cells were significantly more proliferative than normal cells (Figure 4c) . In control reactions, only 6.673.1% of CML cells remained undivided while 42.9711.7% of normal cells did not divide (P ¼ 0.009). All treatments resulted in significant inhibition of CML CD34 þ cell proliferation compared to control cells. The combination of imatinib with Ara-C led to significantly greater suppression of proliferation compared with imatinib alone (P ¼ 0.039). Normal cell proliferation was also inhibited by Ara-C, both in the presence and absence of imatinib.
Reduced sensitivity to apoptosis could be related to increased representation of BCR/ABL À cells within the nonproliferating CD34 þ cell population. To investigate this possibility, flow cytometry sorted nonproliferating and proliferating cell populations and analyzed for the frequency of BCR/ABL þ cells by FISH. No significant differences in frequency of BCR/ABL þ cells were seen between nonproliferating and proliferating populations (Table 2) . Reduced sensitivity to imatinib might also be related to reduced BCR/ABL mRNA expression within nonproliferating cells. However, no significant differences in BCR/ ABL mRNA expression between nonproliferating and proliferating CML cells were observed, whether cells were cultured in the presence or absence of imatinib (Table 2) .
Discussion
In previous studies we have shown that residual BCR/ABL þ progenitors can persist in patients achieving CCR on imatinib 17 and that suppression of CML primitive progenitor growth by imatinib is less than that of more mature cells and is largely related to inhibition of proliferation with only a modest increase in apoptosis. 18 In the current study we further investigated sensitivity of CML progenitors to apoptosis and have made the following important observations: (1) CML progenitors were sensitive to diverse proapoptotic stimuli that activate different apoptotic signaling mechanisms. (2) Bcr-Abl kinase inhibition by imatinib did not consistently enhance sensitivity of CML progenitors to these proapoptotic stimuli. (3) There was a clear relationship between cellular proliferation and sensitivity to apoptosis. (4) Combinations of imatinib with apoptosis-inducing agents also failed to induce apoptosis in nonproliferating cells. (5) The persistence of nonproliferating cells was not due to an enrichment of PhÀ cells or decreased expression of Bcr-Abl in the nonproliferative population. These studies implicate nonproliferating leukemia progenitors as a subpopulation of cells that are resistant to apoptotic elimination by targeted therapy by imatinib alone or in combination with apoptosis-inducing agents.
The current study showed that CML CD34 þ cells were more sensitive to apoptosis than normal CD34
þ cells under certain Effect of imatinib on apoptosis in CML and normal CD34 þ cells treated with apoptosis-inducing agents. CML (n ¼ 4) and normal (n ¼ 3) CD34 þ cells were exposed for 48 h to imatinib alone (1 mM), or the indicated apoptosis inducing agents alone (dark gray bars) or in combination with imatinib (1 mM, light gray bars), and analyzed for apoptosis. The increase in percent apoptotic cells is shown. Apoptosis in untreated controls was 38712% for CML samples and 3978% for normal samples. Significant increases compared with controls were determined using one-tailed paired t-tests, and between imatinib treated and untreated cells by two-tailed paired t-tests.
conditions. Previous studies have reported that Bcr-Abl þ cell lines are protected from apoptosis in response to a variety of stimuli. [24] [25] [26] [27] [28] However, other studies indicate that primary CP CML cells may not demonstrate resistance to apoptosis. 29, 30 Increased Bcr-Abl expression in cell lines compared with primary CML progenitors could contribute to differences in apoptotic responses, as high levels of Bcr-Abl expression may be required to provide protection from apoptosis. 31 Differences in the GF milieu may also modulate the cellular response to proapoptotic stimuli through effects on viability and proliferation signaling mechanisms.
Inhibition of Bcr-Abl kinase activity by imatinib has been reported to induce apoptosis in Bcr-Abl expressing cell lines and enhance sensitivity to other apoptosis induced by arsenic [32] [33] [34] and Ara-C. 28, [35] [36] [37] [38] We observed that cotreatment with imatinib enhanced sensitivity of CML CD34 þ cells to arsenic. Consistent with our results, La Rosee et al 32 reported that the combination of imatinib and arsenic significantly decreased colony formation compared to imatinib alone and Puccetti et al 34 reported that the effects of arsenic on apoptosis were independent of Bcr-Abl kinase activity. We also observed that addition of imatinib did not enhance the sensitivity of CML CD34 þ cells to Ara-C. This may be attributed to imatinib-induced inhibition of proliferation since cytotoxicity of Ara-C may be affected by DNA repair capacity, proliferation rate, and cell cycle status. 39 Other studies 28, 37 have reported that the combination of Ara-C and imatinib substantially decreased CML colony formation compared with imatinib or Ara-C alone but did not directly evaluate CD34 þ cell apoptosis. Inhibition of CFC growth may reflect effects on cell proliferation and differentiation in addition to apoptosis.
Others and we have reported that primitive, nonproliferating, CML stem cells demonstrate reduced sensitivity to imatinib. 18, 19 However, these studies could not determine whether retention of nonproliferating cells reflected the antiproliferative effect of imatinib or insensitivity of quiescent cells to imatinib-induced apoptosis. In the present study we directly demonstrate that Effect of imatinib on CFC capacity in CML and normal CD34 þ cells treated with apoptosis-inducing agents. CML (n ¼ 4) and normal (n ¼ 3) CD34 þ cells were exposed for 48 h to imatinib alone (1 mM), the indicated apoptosis inducing agents alone (dark gray bars), or combination of drug and imatinib (1 mM, light gray bars) and then analyzed for progenitor cell growth in CFC assays. The mean number of colonies in untreated controls was 173739 for CML samples and 216715 for normal samples. The percent suppression of CFC is shown. Significant increases in CFC suppression compared with control cells were determined using one-tailed paired t-tests and between imatinib treated and untreated cells by twotailed paired t-tests. Nonproliferating CML progenitors resist apoptosis MS Holtz et al apoptosis induced by imatinib, Ara-C or arsenic alone or in combination is restricted to dividing CML progenitor cells and that nonproliferating, undivided CML CD34 þ cells are protected from apoptosis. Based on previous experience, nondividing cells are likely to be enriched for primitive progenitors under these conditions. 18 Interestingly, the presence of imatinib reduced Ara-C-induced apoptosis within the dividing cell population, suggesting that Bcr-Abl kinase activity contributed to increased sensitivity to Ara-C.
The mechanisms underlying resistance of nonproliferating CML primitive progenitors to apoptosis are not clear. Our studies indicate that reduced sensitivity to apoptosis was not related to increased representation of BCR/ABL À cells or reduced BCR/ABL mRNA expression within the nonproliferating cell population. A relationship between cell proliferation and apoptosis has been observed in many systems. Cells entering into cycle under adverse conditions cannot completely transit the cell cycle and commit to apoptosis instead. 40 In a recent study, measures to reduce cellular proliferation in Bcr-Abl expressing cell lines failed to reduce imatinib-mediated induction of apoptosis, 41 suggesting that resistance of nonproliferating CML progenitors to apoptosis may be related to non-cell-cyclerelated mechanisms. It is possible that characteristics inherent to the nonproliferating cell population, other than their mitotically dormant state, could play a role in resistance to imatinib. These may include increased drug efflux activity 42 or increased expression of antiapoptotic proteins as has been reported for quiescent AML progenitors. 43 An important implication of our studies is that quiescent hematopoietic progenitors may be more likely to survive imatinib treatment. The relative insensitivity of nonproliferating CML progenitors may contribute in part to the persistence of BCR/ABL þ progenitors in patients achieving cytogenetic remission on imatinib therapy. However, additional factors may also contribute to the persistence of malignant progenitors including the presence of subpopulations bearing kinase mutations conferring imatinib resistance, 23 transmission of survival signals from the microenvironment, 44 and acquisition of Bcr-Abl independent abnormalities. 45 Our data suggest that the use of additional agents such as Ara-C and arsenic in combination with imatinib, although increasing apoptosis of proliferating progenitors, may not enhance apoptotic elimination of nonproliferating progenitors. It will be important in future studies to determine the mechanisms underlying resistance of quiescent CML progenitors to apoptosis as well as to investigate other modalities that may be able to induce apoptosis in this resistant population. Jordan and co-workers 46 have shown that inhibition of NF-kB in combination with apoptosis-inducing agents selectively targets leukemic stem cells in AML. Nondividing, malignant progenitors may be susceptible to immune targeting since allogeneic hematopoietic cell transplantation has been associated with long-term molecular remissions in CML. 47 The assays developed here will be of value in investigating potential therapeutic modalities to target quiescent progenitor cells.
To conclude, we have shown that CML CD34 þ cells are sensitive to a range of apoptosis-inducing agents. However, induction of apoptosis by these agents and/or imatinib is largely restricted to proliferating cells. Additional strategies to target quiescent primitive malignant hematopoietic cells may be required to enhance elimination of malignant cells in CML patients treated with imatinib. Analyzed using Q-PCR.
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